Delving into the Latest Updates on Propranolol Hydrochloride with Synapse

Overview

Basic Info

SummaryPropranolol Hydrochloride, a small molecule drug, targets the β-adrenoceptors as an antagonist, exhibiting an assortment of therapeutic effects.. This drug is used to treat various conditions, including hypertension, angina pectoris, atrial fibrillation, atrial premature complexes, bradycardia, and tachycardia. AstraZeneca developed Propranolol Hydrochloride, which received approval on August 18th, 1966. Propranolol Hydrochloride works by blocking the sympathetic nervous system's action on the heart and blood vessels, which ultimately results in a reduction in heart rate, blood pressure, and oxygen demand. Although Propranolol Hydrochloride can be effective in managing these conditions, it can also cause side effects such as fatigue, dizziness, and depression, and as such, it should only be taken under the guidance of a healthcare provider. Careful monitoring of patients for any adverse effects is also necessary. Overall, Propranolol Hydrochloride is a useful medication for managing heart-related conditions, but each individual patient's case should be carefully considered before use.

Drug Type

Small molecule drug

Synonyms

1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol, 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol, beta-Propranolol

+ [38]

Target

β-adrenoceptors

Mechanism

β-adrenoceptors antagonists(Beta adrenergic receptors antagonists)

Therapeutic Areas

NeoplasmsNervous System DiseasesCardiovascular Diseases+ [1]

Active Indication

HypoxiaHemangiomaMigraine Disorders+ [10]

Inactive Indication

Capillary HemangiomaEssential TremorMyocardial Infarction

Originator Organization

AstraZeneca PLC

Active Organization

Pierre Fabre Médicament SAS

Maruho Co., Ltd.Hebei Jizhong Pharmaceutical Co., Ltd.

+ [7]

Inactive Organization

Wyeth Pharmaceuticals LLC

Drug Highest PhaseApproved

First Approval Date

JP (18 Aug 1966),

Angina PectorisAtrial FibrillationAtrial Premature Complexes+ [4]

RegulationOrphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (KR)

Login to view timeline

Structure

Molecular FormulaC16H22ClNO2

InChIKeyZMRUPTIKESYGQW-UHFFFAOYSA-N

CAS Registry318-98-9

The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure.
This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.

Start Date01 Mar 2025

Sponsor / Collaborator

University of Missouri

NCT06445166 / Not yet recruitingPhase 2IIT

A Multicenter Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Adults

Kaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). Lesion progression is driven by abnormal angiogenesis, chronic inflammation, and uncontrolled cell proliferation. KS remains one of the most commonly diagnosed cancers in many African countries where economic constraints prevent successful treatment in most patients. Treatment outcomes in developed countries are also often unsatisfactory in HIV positive patients despite good virological and immunological responses to antiretroviral therapy. Therefore, identification of new oral, safe treatment options for treatment of KS remains a research priority. Given the known anti-angiogenic properties and based on the treatment response with other benign vascular lesions such as infantile hemangioma, propranolol is a good candidate for the treatment of KS. The hypothesis of this study is that treating patients with Kaposi sarcoma with propranolol will result in an overall response rate (complete response rate plus partial response rate) of at least 45%, and that propranolol will be safe and well tolerated in this patient population.

Start Date31 Dec 2024

Sponsor / Collaborator

Washington University School of Medicine

100 Clinical Results associated with Propranolol Hydrochloride

Login to view more data

100 Translational Medicine associated with Propranolol Hydrochloride

Login to view more data

100 Patents (Medical) associated with Propranolol Hydrochloride

Login to view more data

52,594

Literatures (Medical) associated with Propranolol Hydrochloride

01 Mar 2025·BEHAVIOURAL BRAIN RESEARCH

Exploring the contribution of the dopaminergic and noradrenergic systems in the antidepressant-like action of 1-(2-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)phenyl)ethanone in mice

Article

Author: Zuge, Narryman Pinto ; Goulart, Taís Barcelos ; da Rocha, Marcia Juciele ; Presa, Marcelo Heinemann ; Bortolatto, Cristiani Folharini ; Brüning, César Augusto ; Ledebuhr, Kauane Nayara Bahr ; Alves, Diego

1-(2-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)phenyl)ethanone (ETAP) is a novel hybrid compound containing 1,2,3-triazole and acetophenone. It exhibits antidepressant-like effects in male mice, linked to modulation of serotonergic receptors and monoamine oxidase A (MAO-A) inhibition. This study aimed to evaluate the involvement of the dopaminergic and noradrenergic systems, as well as MAO-B activity inhibition, in the antidepressant-like effect of ETAP in male mice, and to evaluate the antidepressant-like effect of ETAP in female mice. Male mice were treated with different dopaminergic and noradrenergic receptors antagonists 15 min before administering ETAP (1 mg/kg, intragastrically, i.g.). The tail suspension test (TST) was performed 30 minutes later. Different male mice were treated with ETAP (1 mg/kg, i.g.), and 30 minutes later, were euthanized to assess MAO-B activity in the prefrontal cortex and hippocampus. To evaluate the antidepressant-like of ETAP in female mice, ETAP (1 mg/kg, i.g.) was administered, followed by the TST and the forced swimming test (FST) 30 minutes later. The dopaminergic antagonists haloperidol (0.05 mg/kg, intraperitoneally, i.p.), SCH23390 (0.01 mg/kg, subcutaneously, s.c.), and sulpiride (50 mg/kg, i.p.), as well the noradrenergic antagonists prazosin (1 mg/kg, i.p.), yohimbine (1 mg/kg, i.p.), and propranolol (2 mg/kg, i.p.), prevented the antidepressant-like effect of ETAP in the TST. MAO-B activity was unaffected by ETAP in both the prefrontal cortex and hippocampus. ETAP (1 mg/kg, i.g.) induced a significant antidepressant-like effect in female mice in the TST and FST. These findings provide valuable insights into the antidepressant-like effect of ETAP, highlighting its potential for developing more effective depression treatments.

01 Mar 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Eco-friendly synchronous spectrofluorimetry coupled with chemometrics for simultaneous determination of ezetimibe and propranolol in pharmaceutical formulations and spiked plasma samples

Article

Author: Alqahtani, Taha ; Alshehri, Adil ; Fatease, Adel Al ; Almrasy, Ahmed A. ; Alqahtani, Ali ; Almrasy, Ahmed A

In this study, synchronous fluorescence spectroscopic methods coupled with chemometric techniques were developed and evaluated for the simultaneous quantification of ezetimibe and propranolol, two commonly prescribed cardiovascular drugs. Both drugs exhibit overlapping native fluorescence, posing a challenge for their selective determination. To address this, chemometric models including partial least squares (PLS) and genetic algorithm-based variable selection (GA) were constructed using a calibration dataset based on a 5² factorial design resulting in 25 synthetic mixtures. The developed method has been optimized to account for factors such as solvent composition, micellar systems, and excitation/emission wavelengths that affect the fluorescence signals. The PLS and GA-PLS models were validated using an independent test set of 13 samples based on central composite design revealing the GA-PLS model provided improved quantitative performance with relative root mean square error of prediction (RRMSEP) values of 1.3939 and 1.0005 % for ezetimibe and propranolol, respectively, compared to 2.2502 and 2.3526 % for the PLS models. Hence, the GA-PLS models were successfully applied for the determination of ezetimibe and propranolol in pharmaceutical formulations and spiked plasma samples. Furthermore, the greenness and blueness of the proposed methods were compared against reported HPLC procedures using the AGREE and BAGI tools, revealing a greener analytical footprint for the developed method and higher analytical practicability posing as an environmental-friendly alternative to the standard HPLC technique.

01 Mar 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Carbon dot-based molecularly imprinted polymer fluorescent sensor for the detection of propranolol in plasma

Article

Author: Li, Ruizhen ; Fu, Dongju ; Liu, Jialin ; Qin, Lei ; Liu, Xuguang ; Liu, Weifeng ; Wang, Moeiling

Propranolol, a medication used to treat cardiovascular diseases, can be harmful when overdosed and hazardous to ecosystems if released into the environment. Here, a new molecularly imprinted fluorescent sensor was developed from carbon dots through a sol-gel method. Carbon dots served as both the fluorescent signal and the carrier, with propranolol as the template molecule and 3-aminopropyltriethoxysilane as the functional monomer to be grafted on carbon dots' surface. A novel detection method was established for the efficient, rapid, and cost-effective detection of propranolol in human plasma through quantitative analysis by using a fluorescence spectrophotometer and an ultraviolet spectrophotometer. Under the optimal conditions, the detection range of 0.5-4 mg L^-1, the detection limit of 0.092 mg L^-1, the imprinting factor of 2.42, and the detection response time of 2 min were achieved. The prepared carbon dot-based molecularly imprinted fluorescent sensor was proved to have a wide accurate linear range, low detection limit, and very short response time, and can detect lower analyte concentrations with higher detection accuracy.

29

News (Medical) associated with Propranolol Hydrochloride

27 Dec 2024

·www.businesswire.com

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

CHICAGO--( BUSINESS WIRE )--Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. (“GPCR Therapeutics”) on December 24, 2024, aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR Therapeutics’ ongoing drug development pipelines. Through this acquisition, Exicure plans to secure key technical personnel by purchasing all shares of GPCR USA held by GPCR Therapeutics. Following this, Exicure intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, which is currently in Phase 2 clinical trials with the FDA, along with its related patents and intellectual property (IP). By acquiring excellent research personnel and clinical pipelines, Exicure aims to advance as a clinical-stage biotech company. GPCR Therapeutics plans to successfully finalize ongoing clinical trials involving stem cell mobilizers (SCM) targeting multiple myeloma patients and prepare for clinical studies related to acute myeloid leukemia (AML). The market size for the ongoing Phase 2 trials is estimated to be around $1 billion to $2 billion annually. Moreover, Exicure plans to engage in collaborative research and development in various forms for GPCR Therapeutics’ ongoing research in immuno-oncology, fibrosis treatments, and obesity therapies. GPCR Therapeutics, the partner with Exicure in this MOU, is a South Korean drug development company specializing in GPCR (G Protein-Coupled Receptor, “GPCR”), which represents over one-third of all drug targets. GPCR Therapeutics has secured target patents around prominent GPCRs such as CXCR4 and possesses multiple pipelines addressing blood cancers and solid tumors, genetic disorders, idiopathic pulmonary fibrosis, and obesity, including ongoing Phase 2 trials in the U.S. for multiple myeloma. Dr. Pina Cardarelli, who previously served as Vice President at Bristol-Myers Squibb, where she led the development of the first-ever immuno-oncology drugs, Yervoy (ipilimumab) and Opdivo (nivolumab), has served as the Chief Scientific Officer (CSO) of GPCR Therapeutics since 2019. In 2021, GPCR Therapeutics established a subsidiary in the U.S. to align its R&D with global pharmaceutical standards and demands. During the American Society of Hematology (ASH) conference held from December 7-10, 2024, GPCR Therapeutics presented three exhibits detailing: (1) interim results from ongoing Phase 2 trials, (2) data on enhancing treatment efficacy for acute myeloid leukemia (AML), and (3) preclinical data on boosting T cell responses to offer various therapies, including in vivo CAR-T. Additionally, on December 24, 2024, Exicure completed the $8.7 million capital investment. Combined with the $2 million capital investment executed on December 9, 2024, the $1.3 million raised in November, and an expected additional $4 million, the Company plans to secure a total of $14 million in capital investments. The funds will primarily be used for the acquisition of GPCR USA, clinical trial costs, and its ongoing operations. About GPCR Therapeutics, Inc. GPCR Therapeutics, Inc., headquartered in Seoul, South Korea, is a clinical-stage international biopharmaceutical company with an innovative approach to developing therapeutics built on its proprietary GPCR data. The company’s lead small molecule asset, GPC-100/Burixafor, targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in various cancers. GPCR Therapeutics is currently conducting a Phase 2 clinical trial in the U.S. to assess the efficacy of the combination of GPC-100 and propranolol in patients with multiple myeloma. The company is also actively collaborating with domestic and international biotechnology firms. By targeting the unique pharmacology of GPCR pairs, GPCR Therapeutics aims to develop life-changing treatments for cancer and other diseases. Notably, the interaction between CXCR4 and the beta-2 adrenergic receptor (B2AR) presents an alternative signaling pathway that is synergistically dependent on the activation of both CXCR4 and B2AR. About Exicure, Inc. Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com . Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. There can be no assurance regarding our ability to comply with the Panel’s decision and the applicable listing criteria by the deadline or thereafter. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual outcomes to differ materially from the outcomes expressed or implied by this report. Such risks include, among others, the possibility we will not be able to cure existing listing deficiencies, the possibility of additional deficiencies, the risk that the Company may not adequately comply with the terms of the Panel’s decision, and the risk that Nasdaq will ultimately delist the Company’s common stock. All such factors are difficult to predict and may be beyond the Company’s control. The Company undertakes no obligation and does not intend to update or revise any forward-looking statements contained herein, except as required by law or regulation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.

Phase 2ASHAcquisition

09 Dec 2024

·medcitynews.com

Cala Health Snags $50M for At-Home Tremor Relief Therapy - MedCity News

388813 01: A photo illustration depicts a person typing May 4, 2001 in Denver, CO. National Academy of Sciences estimates that musculoskeletal disorders such as carpal-tunnel syndrome, tendinitis, and lower back pain cost the nation $45 billion to $54 billion in compensation, lost wages, and lower productivity each year. (Photo by Michael Smith/Newsmakers) On Monday, a Silicon Valley-based bioelectronic medicine company raised tens of millions of dollars to help the more than 7 million Americans who struggle with essential tremor (ET). The company, named Cala Health, closed a $50 million funding round co-led by Vertex Growth Fund and Nexus NeuroTech Ventures. All of the company’s existing investors also participated in the round, including GV, Johnson & Johnson, Lux Capital, OSF Ventures and Ascension Ventures. Cala was founded in 2014 as a Stanford University spinout. Its main goal is to give patients a better option for treating their ET — which is a neurological disorder characterized by involuntary shaking that usually affects the hands, head or voice. presented by Market Trends to Watch for Health Systems and Their Specialty Pharmacies The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients. By Jake Gaffey, MBA, Chief Strategy Officer at Shields Health Solutions The condition can have a significant effect on people’s essential abilities, such as writing, eating and speaking, pointed out Cala CEO Deanna Harshbarger. “As a result, these tremors can impact mental health and discourage people from doing what they love. Clinical studies estimate 50% of ET patients suffer from social phobia, and 80% of ET patients suffer from depression that can severely impact quality of life,” she stated. The drugs used most often to treat ET include beta-blockers such as propranolol and an epilepsy drug called primidone. While these medications are effective for some patients, they can also induce a range of undesirable side effects such as fatigue, nausea and depression — and some patients might not be able to take these drugs due to contraindications with comorbidity, Harshbarger noted. There are also surgical options, like deep brain stimulation or ablation — but not all patients are keen on invasive procedures, she added. Exclusive Heard at HLTH 2024: Insights from Innovative Healthcare Executives Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation. By MedCity News Last year, Cala gave ET patients a new option through the commercial launch of its kIQ system, which the company says is the first noninvasive wearable device cleared by the FDA to temporarily relieve tremors in people with ET and Parkinson’s disease. “Our goal is to leverage bioelectronic medicine to transform the standard of care for chronic disease and allow patients to live life fully,” Harshbarger declared. The kIQ system is a wrist-worn device prescribed by physicians to manage a patient’s hand tremors. It senses each patient’s unique tremor signature and individualizes stimulation, Harshbarger said. The at-home therapy system delivers transcutaneous afferent patterned stimulation (TAPS) therapy, meaning it applies specific patterns of electrical stimulation through the skin to modulate neural activity and promote therapeutic effects. Using TAPS, the device noninvasively counteracts the patient’s tremor through the nerves on the wrist, she explained. Once a patient completes an at-home therapy session, they can view their body’s responses via Cala’s online patient portal. Nine out of 10 patients experience tremor reduction with a complete 40-minute session, Harshbarger noted. Medicare, the VA and several commercial health plans pay for the therapy, she said. She also said that Cala has no direct competitors, given there are no other companies selling FDA-cleared, noninvasive neurostimulation devices for the relief of hand tremor. There are some other companies developing devices to treat ET using noninvasive neurostimulation, including Allevion Therapeutics and Encora Therapeutics, but they haven’t cleared regulatory hurdles yet in the U.S. Cala is also currently in the process of developing TAPS therapy-based solutions for other indications, such as cardiology and psychiatry, Harshbarger said.

24 Jul 2024

·pipelinereview.com

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

– SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor – No statistically significant differences were demonstrated between any dose of SAGE-324 and placebo in the change from baseline for the primary endpoint CAMBRIDGE, MA, USA I July 24, 2024 I Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 (BIIB124) as a potential treatment in essential tremor (ET). The KINETIC 2 Study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score, in participants with ET. In addition, there were no statistically significant differences demonstrated for any dose of SAGE-324 versus placebo in the change from baseline to Day 91 on the TETRAS PS Item 4 Total Score or the TETRAS Activities of Daily Living (ADL) Composite Score. Given these results, Sage and Biogen will close the ongoing open label safety study of SAGE-324 in ET and do not plan to conduct further clinical development of SAGE-324 in ET. The companies are evaluating next steps, if any, for other potential indications. “There has been little innovation in the pharmacological treatment of essential tremor over the past 50 years, and people living with this debilitating condition have a pressing need for new treatment options. We are disappointed that the results of the KINETIC 2 Study do not support further development of SAGE-324 in ET. We are grateful to the essential tremor community and study investigators for their contributions to this research,” said Laura Gault, MD, PhD, Chief Medical Officer, Sage Therapeutics. “As always, Sage remains steadfast in our work to develop new treatments for people suffering from brain health conditions.” “We wish to thank the study participants and investigators who made this important research possible. While we share in their disappointment, we believe that the findings add to the collective understanding of this debilitating condition and may help inform the field on potential future research and therapeutic approaches,” said Katherine Dawson, MD, Head of Therapeutics Development Unit, Biogen. KINETIC 2 Study Results The KINETIC 2 Study was designed to evaluate the dose-response relationship of different doses of SAGE-324 on upper limb tremor. The study also evaluated the safety and tolerability of SAGE-324. The primary outcome measure was TETRAS PS Item 4 Total Score at Day 91, and the primary analysis assessed the dose-response relationship across SAGE-324 doses on this measure. Additional analyses evaluated the change from baseline to Day 91 on the TETRAS PS Item 4 Total Score and the secondary endpoint, TETRAS ADL Composite Score, for each dose of SAGE-324 versus placebo. In the study, 147 participants (129 monotherapy and 18 adjunct therapy, on a stable dose of propranolol prior to and during the study) were randomized in approximately equal proportions to placebo, 15 mg, 30 mg, and 60 mg (with uptitration) for a three-month treatment period. About SAGE-324 / BIIB124 SAGE-324 is an investigational oral neuroactive steroid (NAS) GABA A receptor positive allosteric modulator (PAM). NAS GABA A receptor PAMs bind to both synaptic and extrasynaptic GABA A receptors, enhancing inhibitory activity of the GABAergic system, the major inhibitory neurotransmission system in the brain. GABA is the primary inhibitory neurotransmitter in the central nervous system and plays a critical role in maintaining balanced neuronal activity in the brain. GABA dysregulation has been implicated in the pathophysiology of ET. The safety and effectiveness of SAGE-324 have not been established. About Sage Therapeutics Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook , LinkedIn , Instagram , and X . About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. The company routinely posts information that may be important to investors on its website at www.biogen.com . Follow Biogen on social media – Facebook , LinkedIn , X , YouTube . SOURCE: Biogen

Clinical ResultPhase 2

100 Deals associated with Propranolol Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00483	Propranolol Hydrochloride	C07AA05	DB00571

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypoxia	JP	Taiyo Pharma Co., Ltd.	18 Nov 2014
Hemangioma	US	Pierre Fabre SA	14 Mar 2014
Essential Hypertension	JP	Taiyo Pharma Co., Ltd.	01 Aug 1978
Cardiomyopathy, Hypertrophic	US	Wyeth Pharmaceuticals LLC	13 Nov 1967
Coronary Artery Disease	US	Wyeth Pharmaceuticals LLC	13 Nov 1967
Essential Tremor	US	Wyeth Pharmaceuticals LLC	13 Nov 1967
Hypertension	US	Wyeth Pharmaceuticals LLC	13 Nov 1967
Migraine Disorders	US	Wyeth Pharmaceuticals LLC	13 Nov 1967
Myocardial Infarction	US	Wyeth Pharmaceuticals LLC	13 Nov 1967
Angina Pectoris	JP	Taiyo Pharma Co., Ltd.	18 Aug 1966
Atrial Fibrillation	JP	Taiyo Pharma Co., Ltd.	18 Aug 1966
Atrial Premature Complexes	JP	Taiyo Pharma Co., Ltd.	18 Aug 1966
Bradycardia	JP	Taiyo Pharma Co., Ltd.	18 Aug 1966
Pheochromocytoma	JP	Taiyo Pharma Co., Ltd.	18 Aug 1966
Tachycardia	JP	Taiyo Pharma Co., Ltd.	18 Aug 1966
Tachycardia, Sinus	JP	Taiyo Pharma Co., Ltd.	18 Aug 1966

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Capillary Hemangioma	Phase 3	US	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	AU	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	CA	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	CZ	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	FR	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	DE	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	HU	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	IT	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	LT	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	MX	Pierre Fabre SA	01 Jan 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05561751 (ASH2024) Manual	Phase 2	Multiple Myeloma CD34+	20	Propranolol+G-CSF+ Burixafor	fxngekztal(ydpvzjxxfb) = yyadzzlnqf mpmkuwokny (ckzwlcjoce )	Positive	09 Dec 2024
NCT03049306 (ProSAT, CTgov)	Phase 2	Sleep Apnea, Obstructive	24	Placebo Oral Tablet+Propranolol Oral Tablet (Placebo Oral Tablet)	hbiytdfrsp(wygpomkruy) = ddojvnzxzs qojhdeminp (bqthmilysk, tnowiskulv - bnkortwogq) View more	-	05 Sep 2024
				Placebo Oral Tablet+Propranolol Oral Tablet (Propranolol Oral Tablet)	hbiytdfrsp(wygpomkruy) = pndmbhzfzm qojhdeminp (bqthmilysk, zxasooeght - hcheltfxcm) View more
ESC2024	Not Applicable	Ventricular Premature Complexes	-	Propranolol	lzskhtacrs(oipmdjhnaq) = ngrttxluxo ddpklwixni (oabfhrzexv, 7.7)	-	09 Apr 2024
				Propranolol (Catheter Ablation)	lzskhtacrs(oipmdjhnaq) = xuloujswqi ddpklwixni (oabfhrzexv, 7.7)
NCT04757584 (CTgov)	Phase 4	Heart failure with normal ejection fraction \| Heart Failure, Diastolic	9	Beta blockers (Beta Blocker ABAB Sequence)	rpdiqokued(idvrhspxot) = nfrfihbajd kibeiezybr (jrpbakymyx, yeppsfaclk - cjjfsnewbn) View more	-	09 Apr 2024
				Beta blockers (Beta Blocker BABA Sequence)	rpdiqokued(idvrhspxot) = ozamykfiml kibeiezybr (jrpbakymyx, lpftgdezjj - tocapvaqwz) View more
NCT02428205 (CTgov)	Not Applicable	Autistic Disorder \| Heart Septal Defects, Atrial	10	Propranolol (Propranolol Arm)	qoodvoqpve(vxmmwrymik) = jgfjtdfari angvrxkjzk (taboymukjz, wwusuqwmka - lsswkjsnqu) View more	-	04 Mar 2024
				Placebo (Placebo Arm)	qoodvoqpve(vxmmwrymik) = hkmzdxybtr angvrxkjzk (taboymukjz, ivljskjdmv - nhotvmnild) View more
NCT02740166 (Pubmed \| Am J Gastroenterol) Manual	Phase 4	Bleeding esophageal varices cirrhosis	212	EVL plus propranolol till EEV	ohlrgmbpry(ielrzdoxjp) = zyjtvypjxk tibejxekxm (xnkrlvmzfx ) View more	Positive	01 Feb 2024
				EVL plus continupropranolololol	ohlrgmbpry(ielrzdoxjp) = uxkrzdqjsm tibejxekxm (xnkrlvmzfx ) View more
EADV2023	Not Applicable	Capillary Hemangioma	50	Oral propranolol	sogeilfbrj(fvetbixosj) = were seen only in very few cases tnbpkmjxxm (rhhbizvozs )	Positive	11 Oct 2023
NCT04299438 (PROPEL, CTgov)	Phase 3	Pregnancy, Prolonged \| Duration of labor	164	Propranolol Hydrochloride (Propranolol)	twwjgskpox(yhglsyfocg) = hqulzwehte wxehbfvglt (skoxlgzivd, gxetstiwzi - krjwspstby) View more	-	23 Aug 2023
				Saline (Placebo)	twwjgskpox(yhglsyfocg) = lnbizveere wxehbfvglt (skoxlgzivd, fqubwwtvaa - avuhkaogiq) View more
NCT01322048 (Pubmed)	Phase 2	Brain Injuries, Traumatic	47	Propranolol and Clonidine	uakhyslvkf(tcrybrvsxr) = wpfzsfijwd gvsztpkqoa (aedxehlley, ( - 5.4, 5.8)) View more	-	09 Jun 2023
NCT04299438 (Pubmed \| Obstet Gynecol)	Phase 3	-	349	Propranolol	uocngumzxk(jmmkkeolbo) = kkrefrfstb qguceavyvg (bhycktczcp )	-	08 Jun 2023
				Placebo	uocngumzxk(jmmkkeolbo) = ufvdkldeql qguceavyvg (bhycktczcp )